Grantham, Mayo, Van Otterloo & Co (GMO)’s Enanta Pharmaceuticals ENTA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50,300	Closed	-$2.3M	–	825
2020 Q3	$2.3M	Sell	50,300 -36,800	-42%	-$1.78M	0.02%	382
2020 Q2	$4.37M	Buy	87,100 +5,800	+7%	+$300K	0.03%	264
2020 Q1	$4.18M	Buy	+81,300	New	+$4.33M	0.03%	269
2018 Q2	–	Sell	-6,700	Closed	-$542K	–	571
2018 Q1	$542K	Sell	6,700 -5,600	-46%	-$431K	﹤0.01%	475
2017 Q4	$722K	Buy	+12,300	New	+$616K	﹤0.01%	391

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s ENTA Position: Q4 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 50,300 shares — an estimated $2.3M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ENTA in Q4 2017 and held it in 5 quarters. The position peaked at $4.37M in Q2 2020. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 50,300 Enanta Pharmaceuticals shares in Q4 2020, an estimated $2.3M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Enanta Pharmaceuticals position peaked at $4.37M in Q2 2020.
151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2020, filed 12 Feb 2021.